Merck & Co., Inc. provided earnings guidance for full-year 2024. For the year, company expects sales to be between $63.1 billion and $64.3 billion, including a negative impact of foreign exchange of approximately 3% at mid-April 2024 exchange rates.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
129.6 USD | -0.64% | +0.26% | +18.83% |
05-08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
05-08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.83% | 330B | |
+32.95% | 700B | |
-4.97% | 358B | |
+3.54% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+6.70% | 161B | |
-1.81% | 157B | |
+3.70% | 124B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024